Skip to content

Seprafilm® for Prevention of Adhesions at Repeat Cesarean

Randomized Double-Blind Controlled Study to Determine if Seprafilm® Reduces Adhesions After Primary Cesarean Section

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00697606
Acronym
SPARC
Enrollment
450
Registered
2008-06-16
Start date
2008-07-31
Completion date
2011-06-30
Last updated
2015-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesion Formation After Primary Cesarean Delivery

Keywords

Seprafilm®, cesarean, adhesions, primary, repeat

Brief summary

Adhesion formation is a result of abdominal and pelvic surgery and is a cause of such diseases as chronic pain syndrome, bowel obstruction and infertility. Both patients and surgeons suffer when adhesions are encountered, since the surgery becomes more intense, lengthy, and complicated. Seprafilm® has been shown to limit the formation of adhesions in gynecologic and abdominal surgery. Limited data is available on the effectiveness of Seprafilm® in the prevention of abdominal wall and pelvic adhesions at the time of cesarean section. Adhesions at the time of repeat cesarean make the surgery frustrating and complex, with difficult lysis of adhesions being the cause of morbidities such as bladder damage, increased blood loss, and longer operating times. The objective of this definitive project is to define the extent of reduction of adhesion formation of Seprafilm® when used at the time of primary cesarean section. Women undergoing primary cesarean section will be randomized for Seprafilm® application, and the incidence and grade of adhesions at repeat cesarean will be determined.

Detailed description

This is a prospective randomized double-blinded study. Patients will be randomized prior to primary cesarean section to either the study arm (Seprafilm® placement) or control arm (nothing placed). Seprafilm® will be placed over the repaired uterine incision and over the anterior aspect of the uterus prior to closure of the fascia (2 to 3 sheets per patient). Randomization will be by opaque envelops containing group assignment. Participants and surgeons will be blinded to group designation at the time of repeat cesarean. The surgeon will be asked to grade the adhesions at the time of repeat cesarean.

Interventions

DEVICESeprafilm®

Seprafilm® placed at time of primary cesarean

OTHERControl

no Seprafilm® used at primary cesarean

Sponsors

Abington Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Pregnant women after 24 weeks' gestation. 2. First cesarean delivery. 3. Age \> 18 years. 4. Cesarean to be performed by a participating surgeon. 5. Non-closure of the visceral or parietal peritoneum.

Exclusion criteria

1. Any prior abdominal surgery including prior cesarean, laparoscopy, appendectomy, cholecystectomy or any uterine adnexal or bowel surgery. 2. Clinical diagnosis of chorioamnionitis. 3. Women having tubal ligation at the time of primary cesarean. 4. Inability to obtain informed consent.

Design outcomes

Primary

MeasureTime frame
To determine if Seprafilm® decreases the incidence of adhesion formation by 50% after primary cesarean.at repeat cesarean

Secondary

MeasureTime frame
To determine to what extent Seprafilm® decreases the incidence of adhesion formation.at repeat cesarean
To determine the incidence of adhesion formation during repeat cesarean delivery.at repeat cesarean
To evaluate complication rates in those with Seprafilm® versus those without during repeat surgery by examining length of operating times, blood loss, bladder injuries, and Apgar scoresat repeat cesarean
To determine the incidence of fertility issues in women having Seprafilm® placed during primary cesarean delivery versus those not having Seprafilm® placed. Participating women will be contacted by telephone every 4 months.ongoing during trial

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026